-
In the new clinical era, how to follow the blinding principle of clinical trials?
Time of Update: 2022-08-15
Emergency unblinding refers to obtaining information on the treatment grouping of a single or part of subjects in emergency situations through pre-established standard operating procedures based on subject safety considerations and other special reasons in accordance with the provisions of the clinical trial protocol .
-
Seeing "her power": within one day, many pharmaceutical companies announced new female executives!
Time of Update: 2022-08-15
Among them, on July 28, the company announced that its board of directors received written resignation reports from director and general manager Wang Hongxin and deputy general managers Yuan Yingsheng and Chen Jing According to the company's previous announcement, the senior executives of China Pharmaceutical changed frequently during the year.
-
Recently, domestic pharmaceutical companies ADC drugs have performed well in overseas markets!
Time of Update: 2022-08-15
In addition, on July 26, Kelun Pharmaceuticals just announced that it has reached a research and development cooperation and license agreement with Merck & Co. for ADC drugs (Project B) for the treatment of solid tumors, involving a total amount of over 900 million US dollars .
-
Pharmaceutical companies are competing for the beauty track, and pharmacies are also accelerating their entry
Time of Update: 2022-08-15
. It is worth noting that, in addition to pharmaceutical companies, some leading chain pharmacies have also begun to boldly promote the process of cosmeceutical franchises and deploy cosmeceuticals under the background of large-scale procurement and medical insurance control fees that have greatly squeezed the profits of the pharmaceutical retail industry.
-
The world's top 10 generic drug giants, who is carrying the load, and who is "running naked"?
Time of Update: 2022-08-15
It is worth noting that although Teva and Novartis' Sandoz are ranked first or second in the world, they are also the only two companies in the TOP10 list whose sales performance of generic drugs has declined, with a negative growth of about 3% .
-
【Know·Chen】Dongchen Pharmaceutical is not just an MCC manufacturer!
Time of Update: 2022-08-15
Some instruments and equipment of Dongchen Pharmaceutical Dongchen Pharmaceutical Qualification and Honor December 2021: Microcrystalline cellulose was activated under CDE registration number F20180000805 for use in pharmaceutical production .
-
Competing for the $20.7 billion antibody-conjugated drug market, many pharmaceutical companies have "going overseas" one after another
Time of Update: 2022-08-15
2 antibody-drug conjugate SYSA1801 in large-scale Development and commercialization rights outside of China For example, on July 28, CSPC announced that its subsidiary CSPC Jushi Biology signed an exclusive licensing agreement with Elevation Oncology, and Elevation Company will obtain CSPC Jushi Bio's innovative anti-Claudin18.
-
China Pharmaceutical Packaging Association organized a seminar on hollow capsule standards
Time of Update: 2022-08-15
The association will guide member units to actively participate in standardization activities at home and abroad, cooperate with the work of Zhejiang Institute, carry out relevant special research work, and jointly promote the high-quality development of the hollow capsule industry .
-
11 pharmaceutical companies have been surveyed by more than 20 institutions, and nearly half of them have disclosed their performance results.
Time of Update: 2022-08-15
. Among them, Kaili Medical announced on July 7 that it is expected to achieve a net profit of 160 million to 200 million yuan attributable to shareholders of listed companies in the first half of 2022, an increase of 46.
-
$90 million development milestone payment!
Time of Update: 2022-08-15
On August 5, Kelun Pharmaceutical announced that its holding subsidiary Kelun Botai will exclusively license its biological macromolecular tumor project A (SKB264) with independent intellectual property rights to MSD in May 2022 to conduct ( China includes mainland China, Hong Kong, Macau and Taiwan) regional research, development, manufacturing and commercialization .
-
Domestic pharmaceutical companies are accelerating their entry into the diabetes drug market!
Time of Update: 2022-08-15
Sugar drugs have been approved for marketing one after another At present, driven by multiple factors such as the continuous growth of diabetes patients in China, the successive entry of new diabetes treatment drugs into the medical insurance catalog, and the enhancement of patients' ability to pay, more and more domestic companies have begun to accelerate their deployment in this field.
-
In order to accelerate innovation, domestic pharmaceutical companies are "grouping together"
Time of Update: 2022-08-15
Recently, China Resources Double Crane issued an announcement to sign the "Strategic Cooperation Agreement" and "Azvudine Tablet Entrusted Processing and Production Framework Agreement" with Real Bio. Expand cooperation in the field .
-
The listing application of Chia Tai Tianqing TQ-B3101 capsules was accepted
Time of Update: 2022-08-15
. TQ-B3101 is a novel small molecule receptor tyrosine kinase inhibitor targeting ALK/ROS1/MET .
. TQ-B3101 is a novel small molecule receptor tyrosine kinase inhibitor targeting ALK/ROS1/MET .
Preclinical studies have shown that the drug has good antitumor activity and duration of efficacy .
-
Guangdong's biopharmaceutical industry is full of innovative vitality!
Time of Update: 2022-08-15
In recent years, with the support of a series of favorable policies for the research and development of innovative traditional Chinese medicines, both the number of applications and the number of approvals have increased significantly .
-
How are Chinese standards for pharmaceutical excipients harmonized with ICH Q3C?
Time of Update: 2022-08-15
Three, "Chinese Pharmacopoeia" pharmaceutical excipient standards and ICH Q3C coordination four parts China began to pay attention to the control requirements of residual solvents in drugs.
Three, "Chinese Pharmacopoeia" pharmaceutical excipient standards and ICH Q3C coordination four parts China began to pay attention to the control requirements of residual solvents in drugs.
-
Shanghai Internet diagnosis and treatment realizes cross-hospital follow-up consultation and dispensing to improve medical accessibility
Time of Update: 2022-08-15
. Zhao Dandan said that the health departments of all districts will further optimize the acceptance and approval process of "Internet hospitals" and "Internet diagnosis and treatment service methods", strengthen business guidance for medical institutions, and encourage qualified medical institutions to apply for Internet diagnosis and treatment services as much as possible .
-
CPhI & P-MEC China 2022 postponed to December
Time of Update: 2022-08-15
After fully listening to the opinions and feedback of relevant parties, and actively communicating with the exhibition hall and relevant departments, the exhibition organizer co-organized a comprehensive research decision: the 21st World Pharmaceutical Raw Materials China Exhibition and the 16th World Pharmaceutical Machinery and Packaging Equipment The CPhI & P-MEC China 2022 has been postponed to December 20-22, 2022, and the venue remains unchanged at the Shanghai New International Expo Center .
-
XRF/Solid Waste Analysis Standards/Hazardous Elements Determination Sharing is collected!
Time of Update: 2022-08-15
[Pharmaceutical Network Conference Forum] At 14:00 on June 23, 2022, a webinar on elemental analysis of solid waste and hazardous waste has been presented on the environmental protection online HB li
-
A unified national medical insurance information platform covering 1.36 billion insured persons has been fully established
Time of Update: 2022-08-15
According to the latest news from the National Medical Insurance Administration, a unified national medical insurance information platform has been fully established, and it has been launched in 31 p
-
Hengrui's class 1 new drug is listed on the market!
Time of Update: 2022-08-15
Domestic review and approval · new trends In this issue, CDE has 54 acceptance numbers (36 varieties) reported to update the production management status. Among them, Liaoning Haisco's Cyclopofol Inj
